- Annual Meetings
- Continuing Education
- Career Center
|AVA SPOTLIGHT: GENENTECH AND ISAVE THAT LINE!|
AVA SPOTLIGHT: GENENTECH AND ISAVE THAT LINE!
ENSURING PATENCY FOR CENTRAL VENOUS ACCESS DEVICES (CVADs)
Ensure Patency is the fifth of the five pillars of the I SAVE That Line campaign, developed over a decade ago by the Association for Vascular Access (AVA). Its intent is to drive comprehensive best practices around catheter care and maintenance.
AVA Platinum Industry Partner Genentech uses the ISAVE campaign as a vehicle to drive optimal and holistic vascular access procedures and device safety. That fifth pillar is closely aligned to its mission of ensuring patients continue to have central line access for their life-sustaining therapies.
“If you’re ensuring catheter patency but underperforming in the other vital areas of care and maintenance, you’re not keeping your patient safe,” AVA CEO Ramzy Nasrallah said. “The ISAVE campaign isn’t a series of choices for delivering optimal outcomes and reducing risk; it’s a philosophy that must be adopted intact.
“Genentech has embraced ISAVE from the beginning. They are committed telling the whole story, not just a part of it.”
CVAD patency is an essential part of safe patient care. Partial or complete occlusions must be treated expeditiously to prevent harm to the patient.
“It is not optional to verify a free-flowing blood return prior to the administration of infusates,” AVA Director of Clinical Education Judy Thompson said. “This simple action can detect something as minor as the start of a partial occlusion, or as serious as an erosion through the vasculature into the plural space.”
While Genentech utilizes the Ensure Patency piece of the ISAVE campaign ahead of the others, the entire movement symbolizes essential pieces for all vascular access professionals.
Simple and affordable for any healthcare facility to adopt, ISAVE is a no-brainer for anyone involved in vascular access and safety.
The Association for Vascular Access (AVA) is an organization of healthcare professionals founded in 1985 to support and promote the specialty of vascular access. The mission of AVA is to represent and advance the vascular access specialty and community and define standards of vascular access through an evidence-based approach to enhance healthcare and patient outcomes. Today, its multidisciplinary membership advances research, provides professional and public education to shape practice and enhance patient outcomes, and partners with the device manufacturing community to bring about evidence-based innovations in vascular access. To learn more, visit www.avainfo.org.
Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com